ClinicalTrials.gg
RecruitingNCT07587723Updated Oct 15, 2026

A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag

An observational study in Immune Thrombocytopenia, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
150
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Started
2026
with 2 others
Observational
3 of 17
2 open now
Registered
14th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is one of 3 that started in 2026, is one of 3 observational ones, and was the 14th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy.

This study will use secondary data provided by health care professionals (HCPs) for a sample of primary ITP patients, and primary data from a structured HCP survey. Data will be collected from HCPs working in various clinical centers across the United States (US), United Kingdom (UK), and Germany.

03

Conditions studied

  • Immune Thrombocytopenia

Keywords

  • Primary Immune Thrombocytopenia
  • Eltrombopag
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with primary ITP who were treated with eltrombopag following corticosteroid treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

HCP inclusion criteria:

  1. A licensed HCP (e.g., internal medicine specialist, hematologist, hematologist-oncologist or immunologist etc.) involved in the management of adult patients with primary ITP.
  2. Actively involved in treatment decision-making for primary ITP patients at the time of the study.
  3. Have a minimum of 3 years of experience managing patients with primary ITP.
  4. Currently, managing an average of at least 2 adult primary ITP patients per month, including those treated with eltrombopag.
  5. Able and willing to complete a web-based survey (approximately 60 to 70 minutes) and abstract data from 2 eligible patient charts.
  6. Practicing in one of the study countries (US, UK, or Germany).
  7. Have access to a computer or mobile device with internet connectivity to complete the survey.
  8. Not listed as inactive or retired in the panel database.

Patient-level inclusion criteria:

  1. Confirmed diagnosis of primary ITP.
  2. Aged ≥18 years at the time of diagnosis.
  3. Received therapy (with or without intravenous immune globulin [IVIg]).
  4. Initiated eltrombopag treatment (with or without corticosteroids) as first non-steroidal ITP treatment between 01 January 2020 and 31 December 2024.
  5. Have at least 6 months of follow-up data available after the index date (unless deceased within that period).

Exclusion criteria

Exclusion criteria:

HCP exclusion criteria:

  1. Currently employed by a pharmaceutical company or regulatory authority involved in the approval or marketing of treatments for primary ITP.
  2. Unable to provide data for patients who meet the study's inclusion criteria.
  3. Not currently managing patients with primary ITP or are not involved in treatment decisions for these patients.

Patient-level exclusion criteria:

1. Diagnosis of Evans syndrome, secondary ITP, or non-immune thrombocytopenia.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Eltrombopag Cohort

    Adult patients diagnosed with primary ITP who initiated eltrombopag treatment between 01 January 2020 and 31 December 2024 following corticosteroid treatment.

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Patients Achieving an Initial Platelet Response Within 12 Weeks of Start of Treatment

    Initial platelet response is defined as a platelet count ≥50 × 10\^9/L.

    Time frame: 12 weeks

Secondary outcomes

  1. Number and Percentage of Patients Achieving an Initial Complete Platelet Response Within 12 Weeks of Start of Treatment

    Complete platelet response is defined as a platelet count of ≥100 × 10\^9/L.

    Time frame: 12 weeks

  2. Number and Percentage of Patients Achieving a Partial Platelet Response Within 12 Weeks of Start of Treatment

    Partial platelet response is defined as a platelet count of ≥30 × 10\^9/L.

    Time frame: 12 weeks

  3. Number and Percentage of Patients With No or Suboptimal Platelet Response Within 12 Weeks of Start of Treatment

    No or suboptimal platelet response is defined as a platelet count of \<30 × 10\^9/L.

    Time frame: 12 weeks

  4. Number and Percentage of Patients Achieving Clinically Meaningful Platelet Response Thresholds Within 12 Weeks of Start of Treatment

    Clinically meaningful platelet response thresholds as indicated by a platelet count increase from a pretreatment value \<30 × 10\^9/L, and/or documentation of improvement in clinical symptoms such as bleeding.

    Time frame: 12 weeks

  5. Time to Platelet Response

    Platelet response is defined as a platelet count ≥50 ×10\^9/L.

    Time frame: Up to 4 years and 6 months after treatment initiation

  6. Platelet Counts at Eltrombopag Treatment Initiation

    Time frame: Day 1

  7. Platelet Counts at Eltrombopag Treatment Discontinuation

    Time frame: Up to 4 years and 6 months after treatment initiation

  8. Number and Percentage of Patients With Bleeding Symptoms During Eltrombopag Treatment

    Time frame: Up to 4 years and 6 months after treatment initiation

  9. Duration Between ITP Diagnosis and Eltrombopag Treatment Initiation

    Time frame: Up to 6 years prior to Day 1 of treatment

  10. Number and Percentage of Patients With Concomitant Corticosteroid Treatment During Eltrombopag Treatment

    Time frame: Up to 4 years and 6 months after treatment initiation

  11. Number and Percentage of Patients With Concomitant Corticosteroid Treatment Withdrawn During Eltrombopag Treatment

    Time frame: Up to 4 years and 6 months after treatment initiation

  12. Time to Eltrombopag Treatment Discontinuation

    Time frame: Up to 4 years and 6 months after treatment initiation

  13. Number of Patients by Reason for Eltrombopag Initiation

    Time frame: Up to 6 years prior to Day 1 of treatment

  14. Number of Patients by Reason for Eltrombopag Discontinuation

    Time frame: Up to 4 years and 6 months after treatment initiation

  15. Baseline Demographics

    Time frame: Up to 6 years prior to Day 1 of treatment

  16. Number of Prior Corticosteroid Treatment Courses

    Time frame: Up to 6 years prior to Day 1 of treatment

  17. Duration of Prior Corticosteroid Treatment Courses

    Time frame: Up to 6 years prior to Day 1 of treatment

  18. Number of Patients by Comorbidities

    Time frame: Up to 6 years prior to Day 1 of treatment

  19. Number of Patients by HCP-reported Reason for Eltrombopag Initiation

    Time frame: Up to 6 years prior to Day 1 of treatment

  20. Number of Patients by HCP-reported Factors Influencing Selection of Eltrombopag as Second-line Treatment

    Factors influencing selection include platelet count, bleeding symptoms, comorbidities, prior treatment response, ease of administration, safety profile, guideline recommendation, and other.

    Time frame: Up to 6 years prior to Day 1 of treatment

  21. Number of Patients by Location of Eltrombopag Prescription

    Time frame: Up to 4 years and 6 months after treatment initiation

  22. Number of Patients by Type of Provider of Eltrombopag Treatment Initiation

    Providers include general practitioner, immunologist, hematologist, internal medicine specialist, and other.

    Time frame: Day 1

  23. Number of Patients Categorized by Typical Duration Between ITP Diagnosis and Eltrombopag Initiation as Reported by the HCP

    Typical duration between diagnosis and treatment initiation categorized as \<3 months, 3-6 months, 6-12 months, \>12 months.

    Time frame: Up to 6 years prior to Day 1 of treatment

  24. Number of Patients by Corticosteroid Use During Eltrombopag Treatment as Reported by the HCP

    Corticosteroid use categorized as never, rarely, sometimes, often, or always.

    Time frame: Up to 4 years and 6 months after treatment initiation

  25. Number of Patients by HCP-reported Indicators for Treatment Escalation or Discontinuation

    Indicators for treatment escalation or discontinuation include lack of platelet response, bleeding symptoms, adverse events, stable response, patient preference, and other.

    Time frame: Up to 4 years and 6 months after treatment initiation

  26. Number of Patients by Common Reasons for Eltrombopag Discontinuation as Reported by the HCP

    Time frame: Up to 4 years and 6 months after treatment initiation

  27. Number of Patients by the HCP-reported Treatment Success With Eltrombopag

    Treatment success categorized as rapid platelet increase, sustained response, bleeding control, minimal side effects, improved quality of life, and other.

    Time frame: Up to 4 years and 6 months after treatment initiation

  28. Number of Patients by Patient Characteristics Associated With Better Eltrombopag Response as Reported by the HCP

    Patient characteristics include younger age, no comorbidities, early initiation post-diagnosis, prior corticosteroid response, and other

    Time frame: Up to 4 years and 6 months after treatment initiation

  29. Number of Patients by Patient Characteristics Associated With Poor Eltrombopag Response as Reported by the HCP

    Patient characteristics include multiple comorbidities, delayed initiation, prior treatment failure, and other.

    Time frame: Up to 4 years and 6 months after treatment initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Sep 2028, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 14, 2026
StartActual
Jun 25, 2026
Primary completionEst.
Sep 29, 2028
CompletionEst.
Sep 29, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07587723
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Jun 25, 2026
Primary completion
Sep 29, 2028 (estimated)
Completion
Sep 29, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion